Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial melphalan for unilateral group D retinoblastoma
NCT02097134Phase 1Completed
- Sponsor
- Children's Oncology Group
- Start
- Oct 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of melphalan in retinoblastoma (Rb), sponsored by Children's Oncology Group. Primary endpoint: Number of Patients Experiencing Feasibility Failure at 4 months. Started Oct 2014; status: completed.
02
Drugs
melphalan
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT02097134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097134.